Company: INMB
Filing Date: 2025-06-10
Form Type: 8-K
Source: 0001213900-25-053051
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-06-10
Form: 8-K
Item: Item 5.07
Chunk 1
---
 of future non-binding advisory votes on resolutions approving future named executive officer compensation.

     1 Year      2 Years        3 Years      Abstentions      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────────────
  1,093,716       42,941      9,612,475          112,884             5,442,095  

In accordance with the voting results on this
proposal, the Company’s board of directors has determined that the Company shall hold an advisory vote on executive compensation
every three years until the next required say-on-frequency vote.

Proposal Five: Approval of the Second Amended
and Restated INmune Bio Inc. 2021 Stock Incentive Plan.

As noted above, the stockholders approved the
Amended Plan.

        For      Against      Abstentions      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────
  9,929,340      838,301           94,375             5,442,095  

Item 8.01. Other Events.

On June 10, 2025, the Company issued a press release announcing the
Company’s collaboration with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia
on the interaction of traumatic brain injury and Alzheimer's disease.

Item 9.01 Financial Statements and Exhibits.